Continuing its recent spate of deal-making, Swiss pharma giant Roche (ROG: SIX) has agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France, for up to 470 million euros ($545 million).
The transaction brings with it Trophos’ proprietary screening platform generated olesoxime (TRO19622), which is being developed for spinal muscular atrophy (SMA) – a rare and debilitating genetic neuromuscular disease that is most commonly diagnosed in children.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze